

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (original) A method of diagnosing or prognosticating a neurodegenerative disease in a subject, or determining whether a subject is at increased risk of developing said disease, comprising determining a level and/or an activity of
 - (i) a transcription product of a gene coding for a cytosolic sulfotransferase family 4A member 1, and/or
 - (ii) a translation product of a gene coding for a cytosolic sulfotransferase family 4A member 1 and/or
 - (iii) a fragment, or derivative, or variant of said transcription or translation product,in a sample obtained from said subject and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby diagnosing or prognosticating said neurodegenerative disease in said subject, or determining whether said subject is at increased risk of developing said neurodegenerative disease.
2. (original) The method according to claim 1 wherein said neurodegenerative disease is Alzheimer's disease.
3. (currently amended) The method according to ~~claims 1 and 2~~ claim 1 wherein said cytosolic sulfotransferase family 4A member 1 is the cytosolic sulfotransferase family 4A member 1 splice variant 1 and/or the cytosolic sulfotransferase family 4A member 1 splice variant 2.

4. (currently amended) A kit for diagnosing or prognosticating a neurodegenerative disease[[,]] ~~in particular Alzheimer's disease~~[[,]] in a subject, or determining the propensity or predisposition of a subject to develop such a disease by the steps of:
- (i) detecting in a sample obtained from said subject a level, or an activity, or both said level and said activity of a transcription product and/or of a translation product of a gene coding for a cytosolic sulfotransferase family 4A member 1, and
 - (ii) comparing said level or activity, or both said level and said activity of a transcription product and/or of a translation product of a gene coding for a cytosolic sulfotransferase family 4A member 1 to a reference value representing a known health status and/or to a reference value representing a known disease status, and said level, or activity, or both said level and said activity, of said transcription product and/or said translation product is varied compared to a reference value representing a known health status, and/or is similar or equal to a reference value representing a known disease status, said kit comprising:
 - [[a]] at least one reagent which is selected from the group consisting of
 - [[i]] (a) reagents that selectively detect a transcription product of a gene coding for a cytosolic sulfotransferase family 4A member 1 and
 - [[ii]] (b) reagents that selectively detect a translation product of a gene coding for a cytosolic sulfotransferase family 4A member 1.
5. (currently amended) A method of treating or preventing a neurodegenerative disease[[,]] ~~in particular Alzheimer's disease~~[[,]] in a subject comprising

administering to said subject in a therapeutically or prophylactically effective amount an agent or agents which directly or indirectly affect an activity and/or a level of

- (i) a gene coding for a cytosolic sulfotransferase family 4A member 1, and/or
 - (ii) a transcription product of a gene coding for a cytosolic sulfotransferase family 4A member 1, and/or
 - (iii) a translation product of a gene coding for a cytosolic sulfotransferase family 4A member 1, and/or
 - (iv) a fragment, or derivative, or variant of (i) to (iii).
6. (original) A genetically altered non-human animal comprising a non-native gene sequence coding for a cytosolic sulfotransferase family 4A member 1, or a fragment, or a derivative, or a variant thereof.
7. (currently amended) The genetically altered non-human animal according to claim 6 wherein said non-human animal is a mammal[[,]] ~~preferably a rodent, more preferably a mouse, a rat or a guinea pig,~~ or an invertebrate animal[[,]] ~~preferably an insect, more preferably a fly such as the fly *Drosophila melanogaster*.~~
8. (currently amended) The genetically altered non-human animal according to ~~claims 6 and 7~~ claim 6, wherein the expression of said genetic alteration results in said non-human animal exhibiting a predisposition to developing symptoms, and/or displaying symptoms of neuropathology similar to a neurodegenerative disease[[,]] ~~in particular symptoms similar to AD.~~
9. (currently amended) The genetically altered non-human animal according to ~~claims 6 and 7~~ claim 6, wherein the expression of said genetic alteration results in said non-human animal which has a reduced risk of developing symptoms similar

to a neurodegenerative disease, ~~in particular a reduced risk of developing symptoms similar to AD~~ and/or which shows a reduction of ~~[[AD]]~~ said symptoms and/or which has no ~~[[AD]]~~ symptoms due to an effect caused by the expression of the gene used to genetically alter said non-human animal.

10. (currently amended) ~~Use of~~ A method of developing diagnostics and therapeutics to treat neurodegenerative diseases, comprising screening, testing, or validating compounds, agents, and modulators using the genetically altered non-human animal according to claim 6 ~~claims 7 to 9 for screening, testing, and validating compounds, agents, and modulators in the development of diagnostics and therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease.~~
11. (currently amended) ~~An assay~~ A method for screening for a modulator of neurodegenerative diseases, ~~in particular Alzheimer's disease~~[[,]] or related diseases or disorders of one or more substances selected from the group consisting of
 - (i) a gene coding for a cytosolic sulfotransferase family 4A member 1, ~~and/or~~
 - (ii) a transcription product of a gene coding for a cytosolic sulfotransferase family 4A member 1, ~~and/or~~
 - (iii) a translation product of a gene coding for a cytosolic sulfotransferase family 4A member 1, ~~and/or~~ and
 - (iv) a fragment, or derivative, or variant of (i) to (iii),said method comprising:
 - (a) contacting a cell with a test compound;
 - (b) measuring the activity and/or level of one or more substances recited in (i) to (iv);

- (c) measuring the activity and/or level of one or more substances recited in (i) to (iv) in a control cell not contacted with said test compound; and
 - (d) comparing the levels and/or activities of the substance in the cells of step (b) and (c), wherein an alteration in the activity and/or level of substances in the contacted cells indicates that the test compound is a modulator of said diseases or disorders.
12. (currently amended) A method of screening for a modulator of neurodegenerative diseases, ~~in particular Alzheimer's disease~~[[,]] or related diseases or disorders of one or more substances selected from the group consisting of
- (i) a gene coding for a cytosolic sulfotransferase family 4A member 1, ~~and/or~~
 - (ii) a transcription product of a gene coding for a cytosolic sulfotransferase family 4A member 1, ~~and/or~~
 - (iii) a translation product of a gene coding for a cytosolic sulfotransferase family 4A member 1, ~~and/or~~ and
 - ~~(v)~~ (iv) a fragment, or derivative, or variant of (i) to (iii),
- said method comprising:
- (a) administering a test compound to a test animal which is predisposed to developing or has already developed symptoms of a neurodegenerative disease or related diseases or disorders in respect of the substances recited in (i) to (iv);
 - (b) measuring the activity and/or level of one or more substances recited in (i) to (iv);

- (c) measuring the activity and/or level of one or more substances recited in (i) or (iv) in a matched control animal which is predisposed to developing or has already developed symptoms of a neurodegenerative disease or related diseases or disorders in respect to the substances recited in (i) to (iv) and to which animal no such test compound has been administered;
 - (d) comparing the activity and/or level of the substance in the animals of step (b) and (c), wherein an alteration in the activity and/or level of substances in the test animal indicates that the test compound is a modulator of said diseases or disorders.
- 13. (original) The method according to claim 12 wherein said test animal and/or said control animal is a genetically altered non-human animal which expresses the gene coding for a cytosolic sulfotransferase family 4A member 1, or a fragment, or a derivative, or a variant thereof, under the control of a transcriptional control element which is not the native a cytosolic sulfotransferase family 4A member 1 gene transcriptional control element.
- 14. (currently amended) An assay for testing a compound, ~~preferably for screening~~ or a plurality of compounds for inhibition of binding between a ligand and a cytosolic sulfotransferase family 4A member 1 protein, or a fragment, or derivative, or variant thereof, said assay comprising the steps of:
 - (i) adding a liquid suspension of said [[a]] cytosolic sulfotransferase family 4A member 1 protein, or a fragment, or derivative, or variant thereof, to a plurality of containers;
 - (ii) adding a compound or a plurality of compounds to be screened for said inhibition of binding to said plurality of containers;

- (iii) adding a detectable ligand[[,]] ~~in particular a fluorescently detectable~~
ligand[[,]] to said containers;
 - (iv) incubating the liquid suspension of said [[a]] cytosolic sulfotransferase
family 4A member 1 protein, or said fragment, or derivative, or variant
thereof, and said compound or compounds, and said ligand;
 - (v) measuring amounts of detectable ligand[[,]] ~~of preferably fluorescence~~
associated with said [[a]] cytosolic sulfotransferase family 4A member 1
protein, or with said fragment, or derivative, or variant thereof; and
 - (vi) determining the degree of inhibition by one or more of said compounds of
binding of said ligand to said [[a]] cytosolic sulfotransferase family 4A
member 1 protein, or said fragment, or derivative, or variant thereof.
15. (currently amended) ~~The use of~~ method of claim 1, comprising determining a
level and/or an activity of protein molecules of SEQ ID NO. 1 and/or SEQ ID
NO. 2, said protein molecules being [[a]] translation products of the gene coding
for a cytosolic sulfotransferase family 4A member 1, or fragments, or derivatives,
or variants thereof[[,]] ~~as diagnostic targets for detecting a neurodegenerative
disease, preferably Alzheimer's disease.~~
16. (currently amended) ~~The use of~~ method of claim 11, wherein said screening is
for a modulator of protein molecules of SEQ ID NO. 1 and/or SEQ ID NO. 2,
said protein molecules being translation products of the gene coding for a
cytosolic sulfotransferase family 4A member 1, or fragments, or derivatives, or
variants thereof, ~~as screening targets for reagents or compounds~~ wherein said
modulator is a reagent or compound for preventing, or treating, or ameliorating a
neurodegenerative disease[[,]] ~~preferably Alzheimer's disease.~~

17. (currently amended) ~~Use of A method for detecting the pathological state of a cell in a sample obtained from a subject, comprising immunocytochemical staining of said cell with~~ an antibody specifically immunoreactive with an immunogen, wherein said immunogen is a translation product of a gene coding for a cytosolic sulfotransferase family 4A member 1, SEQ ID NO. 1 or SEQ ID NO. 2, or a fragment, or derivative, or variant thereof, ~~for detecting the pathological state of a cell in a sample obtained from a subject, comprising immunocytochemical staining of said cell with said antibody~~[[,]] wherein an altered degree of staining, or an altered staining pattern in said cell compared to a cell representing a known health status indicates a pathological state of said cell which relates to a neurodegenerative disease[[,]] ~~preferably to Alzheimer's disease.~~
18. (new) The kit of claim 4, wherein said neurodegenerative disease is Alzheimer's disease.
19. (new) The method of claim 5, wherein said neurodegenerative disease is Alzheimer's disease.
20. (new) The genetically altered non-human animal according to claim 7 wherein said mammal is a rodent, mouse, rat or guinea pig and said invertebrate animal is an insect or a fly.
21. (new) The genetically altered non-human animal according to claim 20 wherein said fly is *Drosophila melanogaster*.
22. (new) The genetically altered non-human animal according to claim 8, wherein said neurodegenerative disease is Alzheimer's disease.
23. (new) The genetically altered non-human animal according to claim 9, wherein said neurodegenerative disease is Alzheimer's disease.

24. (new) The method of claim 10, wherein said neurodegenerative disease is Alzheimer's disease.
25. (new) The method of claim 11, wherein said neurodegenerative disease is Alzheimer's disease.
26. (new) The method of claim 12, wherein said neurodegenerative disease is Alzheimer's disease.
27. (new) The assay of claim 14, wherein said detectable ligand is a fluorescently detectable ligand.
28. (new) The kit of claim 4, wherein said translation product is one or more protein molecules of SEQ ID NO. 1 and/or SEQ ID NO. 2, said protein molecules being translation products of the gene coding for a cytosolic sulfotransferase family 4A member 1, or fragments, or derivatives, or variants thereof.
29. (new) The method of claim 12, wherein said screening is for a modulator of protein molecules of SEQ ID NO. 1 and/or SEQ ID NO. 2, said protein molecules being translation products of the gene coding for a cytosolic sulfotransferase family 4A member 1, or fragments, or derivatives, or variants thereof, wherein said modulator is a reagent or compound for preventing, or treating, or ameliorating a neurodegenerative disease.
30. (new) The method of claim 17, wherein said neurodegenerative disease is Alzheimer's disease.